MARKETS / BALCAO / RDGL
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Vivos Inc. RDGL

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$68,379
▲ 144.3% vs FY2024
EPS · FY25
$-0.01
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-161.0%
Net margin · FY25
-4483.9%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 68,379.00
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.00010.00020.00030.00040.0-0.0201020132016201920222025
0.00010.00020.00030.00040.0-0.02016201920222025

The company lost 4484 cents on every revenue dollar this year.

Per share
USD -0.01
Diluted EPS, FY2025
EPS
0.40.81.2-0.01201020132016201920222025
0.40.81.2-0.012016201920222025

The company pays no cash dividend.

Profitability
-161.0%
Return on equity, FY2025
ROE
0.250.50.751-161.0%201020132016201920222025
0.250.50.751-161.0%2016201920222025
Operating margin-4628.7%
Net margin-4483.9%
Return on assets-149.5%

Each USD of equity lost 161 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+57.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+23.3%
+57.7%
+11.0%
−10.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.46B
Shares outstanding, FY2025
0.070.46201020132016201920222025
0.030.462016201920222025
Change, 5 years+55.8%
Change, 10 years

The share count grew 56% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.9M
total assets, end of FY2025
Total assetsUSD 1.9M
EquityUSD 1.7M
Current ratio14.00×

Equity funds 89% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
0.0
0.0
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.01
−0.01
−0.01
−0.01
−0.01
0.00
−0.01
−0.14
−0.13
−0.46
0.34
−0.06
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−161.0
−165.7
−191.3
−157.9
−337.2
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.46
0.44
0.39
0.36
0.34
0.29
0.18
0.16
0.07
0.03
0.02
1.71
0.12
0.08
0.07
0.07

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed